According to the Governor of Kaluga region Anatoly Artamonov, Kaluga pharmaceutical cluster achieved significant results over the seven years of its existence.
This period was marked by a five-fold increase in the output. For 2017, the industrial production index of the sector reached 167%.
“The output of companies in the pharmaceutical cluster reached 35 billion rubles, that is the best development dynamics not only among the other sectors of regional industry, but in the entire Russian market of medicinal products. Pharmaceutical companies invested 52 billion rubles in establishing their production facilities,” said the head of the region.
Kaluga pharmaceutical cluster has 63 participants, including international and Russian pharmaceutical corporations, medium and small-sized innovative companies, leading research and educational centers. More than 80% of products manufactured in the cluster are finished medicines, and the participants in the cluster employ 9020 people. Pharmaceutical enterprises of the region manufacture about 154 products.
Two companies of Kaluga pharmaceutical cluster received preferences under Special Investment Contracts (SPIC). In 2017, AstraZeneca became the first pharmaceutical company in Russia to sign a SPIC. In 2018, NovaMedica signed the biggest SPIC in Russian pharmaceutical industry to manufacture the innovative medicines. Under the contract, NovaMedica will additionally invest more than 3 billion rubles in the modernization of the enterprise and technology transfer.